Profound Medical (PROF) Stock Price, News & Analysis

Company Overview

Profound Medical (NASDAQ:PROF) is a Canadian-based medical technology company focused on the development and commercialization of innovative therapeutic devices for ablation of soft tissue. The company’s proprietary platforms leverage real-time imaging and computer-assisted treatment delivery to offer minimally invasive alternatives to traditional surgical approaches. Profound Medical’s solutions are designed to address conditions such as prostate cancer, benign prostatic hyperplasia, and uterine fibroids by providing targeted, image-guided tissue ablation.

The cornerstone of Profound Medical’s product portfolio is the TULSA-PRO® system, which combines transurethral ultrasound ablation with continuous magnetic resonance imaging (MRI) monitoring. This integration allows physicians to visualize treatment in real time, adjust parameters on the fly, and ensure thermal ablation is confined to the intended tissue. The company is also advancing research into additional indications and treatment models that may benefit from precise, image-guided energy delivery.

Founded in 2008 under its former name, Sonocare Medical, the company rebranded as Profound Medical in 2014 to reflect its broadened focus on image-guided therapy platforms. Headquartered in Vancouver, British Columbia, Profound Medical operates in key markets across North America, Europe, and select regions in Asia. The company holds or has filed patents covering core technologies, and it collaborates with leading academic institutions and clinical centers to validate and expand the applications of its systems.

Profound Medical is led by a management team with deep expertise in medical devices, imaging, and life sciences commercialization. The company’s board and executive leadership have a track record of guiding healthcare ventures through regulatory approvals, market launches, and strategic partnerships. Through its commitment to precision ablation technology, Profound Medical aims to improve patient outcomes, reduce recovery times, and offer cost-effective therapeutic alternatives for common urological and gynecological conditions.

Key Stats

• Today's Range: $5.85 to $6.22
• 50-Day Range: $4.04 to $6.79
• 52-Week Range: $3.90 to $11.42
• Volume: 49,777 shs
• Average Volume: 65,618 shs
• Market Capitalization: $183.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.50
• Consensus Rating: Buy

Profound Medical Stock Analysis - MarketRank™

Profound Medical scored higher than 53% of companies evaluated by MarketBeat, and ranked 481st out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Profound Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Profound Medical has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Profound Medical are expected to grow in the coming year, from ($1.12) to ($0.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Profound Medical is -4.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Profound Medical is -4.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Profound Medical has a P/B Ratio of 3.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.00% of the float of Profound Medical has been sold short.

Short Interest Ratio / Days to Cover

Profound Medical has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in Profound Medical has recently increased by 10.48%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Profound Medical does not currently pay a dividend.

Dividend Growth

Profound Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.00% of the float of Profound Medical has been sold short.

Short Interest Ratio / Days to Cover

Profound Medical has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in Profound Medical has recently increased by 10.48%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: N/A

News Sentiment

Profound Medical has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Profound Medical this week, compared to 3 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Profound Medical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,201.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 1.52% of the stock of Profound Medical is held by insiders.

Percentage Held by Institutions

47.86% of the stock of Profound Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PROF Stock Analysis - Frequently Asked Questions

How have PROF shares performed this year?

Profound Medical's stock was trading at $7.51 at the beginning of the year. Since then, PROF stock has decreased by 18.9% and is now trading at $6.09.

How were Profound Medical's earnings last quarter?

Profound Medical (NASDAQ:PROF) posted its quarterly earnings results on Thursday, May, 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by $0.07. The business had revenue of $2.62 million for the quarter, compared to analysts' expectations of $4.78 million. Profound Medical had a negative net margin of 269.35% and a negative trailing twelve-month return on equity of 70.41%.
Read the conference call transcript.

How do I buy shares of Profound Medical?

Shares of PROF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Profound Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Profound Medical investors own include Alibaba Group (BABA), Pfizer (PFE), NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA) and Docusign (DOCU).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:PROF
• CIK: 1628808
• Web: www.profoundmedical.com
• Phone: (647) 476-1350
• Fax: 64-7847-3739
• Employees: 150
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.50
• High Stock Price Target: $12.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +88.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$27.82 million
• Net Margins: -269.35%
• Pretax Margin: -269.38%
• Return on Equity: -70.41%
• Return on Assets: -57.22%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 11.31
• Quick Ratio: 10.03

Sales & Book Value

• Annual Sales: $10.68 million
• Price / Sales: 17.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.01 per share
• Price / Book: 3.03

Miscellaneous

• Outstanding Shares: 30,050,000
• Free Float: 29,596,000
• Market Cap: $183.00 million
• Optionable: Optionable
• Beta: 0.49